Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 18/20 | 1.00 |
| ▸ | MAOB | P27338 | 13/20 | 1.00 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | HTR1B | P28222 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | MAOA | P21397 | 8/20 | 0.82 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.66 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14880961 | 1.00 | KDM1A (1.00) | KDM1AMAOBCISD1SLC6A2HTR1B | |
| SCHEMBL21729750 | 1.00 | KDM1A (1.00) | KDM1AMAOBCISD1SLC6A2HTR1B | |
| SCHEMBL14880456 | 1.00 | KDM1A (1.00) | KDM1AMAOBCISD1SLC6A2HTR1B | |
| SCHEMBL14880683 | 1.00 | KDM1A (1.00) | KDM1AMAOBCISD1SLC6A2HTR1B | |
| Hydrochloric Acid SCHEMBL14880813 | 0.98 | KDM1A (1.00) | KDM1AMAOBCISD1SLC6A2HTR1B | |
| Hydrochloric Acid SCHEMBL30283667 | 0.98 | KDM1A (1.00) | KDM1AMAOBCISD1SLC6A2HTR1B | |
| Hydrochloric Acid SCHEMBL20959629 | 0.98 | KDM1A (1.00) | KDM1AMAOBCISD1SLC6A2HTR1B | |
| Hydrochloric Acid SCHEMBL29378943 | 0.98 | KDM1A (1.00) | KDM1AMAOBCISD1SLC6A2HTR1B | |
| Hydrochloric Acid SCHEMBL14880811 | 0.98 | KDM1A (1.00) | KDM1AMAOBCISD1SLC6A2HTR1B | |
| Hydrochloric Acid SCHEMBL16394227 | 0.98 | KDM1A (1.00) | KDM1AMAOBCISD1SLC6A2HTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3397756-B1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | NOVARTIS AG (CH) | 2023-03-08 | — | — | EP | claimed |
| US-20240418723-A1 | SEQUENTIAL TREATMENTS AND BIOMARKERS TO REVERSE RESISTANCE TO KINASE INHIBITORS | QUEEN MARY UNIVERSITY OF LONDON (GB) | 2024-12-19 | — | — | US | disclosed |
| EP-4219689-A2 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | Novartis AG (CH) | 2023-08-02 | — | — | EP | disclosed |
| EP-3397756-B1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | NOVARTIS AG (CH) | 2023-03-08 | — | — | EP | disclosed |